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Background/Aims: Colorectal cancer is associated with different anatom-
ical, biological, and clinical characteristics. We determined the impact of 
the primary tumor location in patients with metastatic colorectal cancer 
(mCRC).
Methods: Demographic data and clinical information were collected from 
1,115 patients from the Republic of Korea, who presented with mCRC be-
tween January 2009 and December 2011, using web-based electronic case 
report forms. Associations between the primary tumor location and the 
patient’s clinical characteristics were assessed, and factors inf luencing 
overall survival were analyzed using Cox proportional hazards regression 
models.
Results: Of the 1,115 patients recruited to the study, 244 (21.9%) had right 
colon cancer, 483 (43.3%) had left colon cancer, and 388 (34.8%) had rectal 
cancer. Liver and lung metastases occurred more frequently in patients 
with left colon and rectal cancer (p = 0.005 and p = 0.006, respectively), 
while peritoneal and ovarian metastases occurred more frequently in 
patients with right and left colon cancer (p < 0.001 and p = 0.031, respec-
tively). The median overall survival of patients with tumors originating 
in the right colon was significantly shorter than that of patients whose tu-
mors had originated in the left colon or rectum (13.7 months [95% confi-
dence interval (CI), 12.0 to 15.5] vs. 18.0 months [95% CI, 16.3 to 19.7] or 19.9 
months [95% CI, 18.5 to 21.3], respectively; p = 0.003). Tumor resection, the 
number of metastatic sites, and primary tumor location correlated with 
overall survival in the univariate and multivariate analyses.
Conclusions: Primary tumor location influences the metastatic sites and 
prognosis of patients with mCRC.
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INTRODUCTION
Colorectal cancer (CRC) represents the third and second 
most frequently diagnosed cancer in men and women, 
respectively. However, CRC mortality rates are high in 
a large number of countries worldwide [1]. In 2012, the 
Korea Central Cancer Registry contained 28,988 cases 
of newly diagnosed CRC. The crude incidence rate was 
an estimated 57.6 (69.3 for men and 45.9 for women) per 
100,000 individuals, making CRC the third most fre-
quently diagnosed cancer, after thyroid and gastric can-
cer [2]. 
CRC is associated with different anatomical, biologi-
cal, and clinical characteristics. The subsite-specific in-
cidences of CRC are approximately 25.0%, 5.0%, 5.0%, 
22.0%, and 27.0% for ascending colon and cecum, trans-
verse colon, descending colon, sigmoid colon, and the 
rectum, respectively [3]. Genetic and epigenetic alter-
ations in CRC differ according to the primary tumor lo-
cation [4]. CRCs associated with germline mutations of 
the APC gene develop in the distal colon in approximate-
ly 60.0% of the cases and in the rectum in approximately 
25.0% of the cases. High microsatellite instability (MSI) 
and mismatch repair deficient colon cancers predomi-
nantly occur in the right colon [5,6]. Treatment for CRC 
also differs in the early stages. Rectal cancer requires 
radio- or chemoradiotherapy, whereas colon cancer 
does not [7]. However, the treatment for metastatic CRC 
(mCRC) is usually the same. A mCRC is treated with fluo-
ropyrimidine and either irinotecan or oxaliplatin, which 
is associated with an increased overall survival (OS) of 
> 2.0 years, with the addition of molecularly targeted 
agents [8]. Vascular endothelial growth factor (VEGF) 
inhibition with a monoclonal antibody, in combination 
with first- or second-line chemotherapy, has been shown 
to prolong survival in mCRC patients [9,10]. Monoclonal 
antibody inhibition of the epidermal growth factor re-
ceptor (EGFR) cetuximab or panitumumab has also been 
associated with improved patient outcomes, but only in 
the absence of RAS gene mutations [11,12]. 
A mCRC registry was designed to collect and evaluate 
data in patients with newly diagnosed primary mCRC. 
In this study, we aimed to evaluate the influence of the 
primary tumor location on the metastatic sites, KRAS 
gene mutation status, treatment patterns, and clinical 
outcomes in mCRC patients.
METHODS
This study was performed by the Colorectal Cancer 
Committee of the Korean Cancer Study Group (KCSG). 
The study was approved by the Institutional Review 
Board of KCSG (KCSG CO12-04) and each of the 22 par-
ticipating institutions and performed in accordance 
with the principles of the Declaration of Helsinki. The 
informed consent was waived. The demographic data 
and clinical information of patients who were newly di-
agnosed with mCRC between January 2009 and Decem-
ber 2011 were reviewed using web-based electronic case 
report forms. Patients aged ≥ 18 years who had patholog-
ically confirmed adenocarcinoma with stage IV mCRC 
at initial diagnosis were enrolled in this study. Patients 
who had squamous cell carcinoma, non-Hodgkin’s lym-
phoma, and neuroendocrine tumors (among others), or 
recurrences of early-stage CRC were excluded. Patient 
demographic data and information on primary tumor 
location, metastatic sites, treatment patterns, and clini-
cal outcomes were collected by a physician or designat-
ed representative. 
Primary tumor location was divided into the right co-
lon, left colon, and the rectum. Tumors originating in 
the cecum, ascending colon, and proximal two-thirds 
of the transverse colon were categorized as cancers aris-
ing in the right colon. Tumors originating in the distal 
third of the transverse colon and sigmoid colon were 
categorized as cancers arising in the left colon. Because 
surgical resection of the primary mCRC had been per-
formed in selected patients, the precise location of the 
primary tumor was difficult to ascertain, especially in 
the transverse colon, rectosigmoid colon, and upper 
rectum. Therefore, patients with transverse colon can-
cer were excluded and we arbitrarily defined rectal can-
cer as that originating in an approximate 15.0 cm region 
from the anal verge. 
The KRAS gene mutations in this report refer to mu-
tations in codon 12 or 13 in exon 2. KRAS genetic test-
ing was performed using samples of paraffin-embedded 
tumor tissues that were sent to a laboratory for analysis 
using the established methods of each institution, in-
cluding peptide nucleic acid-mediated real-time poly-
merase chain reaction clamping, direct sequencing, and 
pyrosequencing. 
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Statistical analyses
The data were summarized using descriptive statistics. 
Continuous variables are represented by the frequency 
distribution, median, standard deviation, and extreme 
values. Categorical variables are represented by percent-
age frequency of each modality and 95% confidence in-
tervals (CIs). For categorical data, group comparisons 
were performed by an analysis of variance provided 
there was a reasonably normal distribution. Otherwise, 
chi-square or Fisher exact tests were performed. Pro-
gression-free survival (PFS) was estimated from the date 
of commencing treatment to the date of disease progres-
sion, or the date of death or last follow-up. OS was de-
fined as the time from the date of pathological diagnosis 
to the date of death from any cause. PFS and OS were 
analyzed using the Kaplan-Meier method. For continu-
ous data, analyses of variance tests were performed. A 
Cox proportional hazards regression model was used in 
the multivariate analysis of factors of OS that were sig-
nificantly different in the univariate analysis. All statis-
tical analyses were conducted using SPSS for Windows 
software version 19.0 (IBM Corp., Armonk, NY, USA). A p 
< 0.05 was considered statistically significant.
RESULTS
Patient characteristics 
In total, 1,166 patients were enrolled by 22 institutional 
members of the KCSG Colorectal Cancer Committee. 
Transverse colon cancers were difficult to divide into 
right and left colon cancers in the absence of surgery. 
Therefore, we excluded 51 patients with transverse colon 
cancer from this study. Of the remaining 1,115 patients, 
685 (61.4%) were men and 430 (38.6%) were women. The 
baseline demographics and disease characteristics are 
summarized in Table 1. Seven hundred and twenty-sev-
en patients (65.2%) presented with metastatic colon can-
cer, including 244 patients (21.9%) with right colon can-
cer, 483 patients (43.3%) with left colon cancer, and 388 
patients (34.8%) with rectal cancer. The median age of all 
patients was 62 years (range, 31 to 94). The most common 
symptom of mCRC was abdominal pain, which occurred 
in 462 patients (41.4%). However, 95 patients (8.5%) were 
asymptomatic. Active treatment (surgical resection with 
or without chemotherapy, or chemotherapy alone) was 
performed in 1,003 patients (90.0%). The remaining 112 
patients received conservative care, such as symptom-
atic control of the intestinal obstruction by colostomy, 
stenting, palliative surgery, or radiation therapy.
Metastatic patterns according to primary tumor lo-
cation 
The most frequent metastatic sites of mCRC include the 
liver, lungs, extra-regional lymph nodes, and peritone-
um. More than half of the patients (52.6%) had a single 
metastatic site, in ascending order, in the liver (35.9%), 
lungs (4.7%), and peritoneum (4.3%). The liver was the 
most frequent metastatic site (75.0%), with or without 
other sites. Liver and lung metastases arose more fre-
quently from primary left colon and rectal cancer than 
right colon cancer (p = 0.005 and p = 0.006, respectively). 
Peritoneal and ovarian metastases arose more frequent-
ly from primary right and left colon cancer than rectal 
cancer (p < 0.001 and p < 0.05, respectively) (Table 2). In 
contrast, no significant differences were observed be-
tween tumors originating from the right colon, left co-
lon, or the rectum with respect to other rarer metastatic 
sites (e.g., the brain, bone, and spleen).
Treatment for metastatic colorectal cancer
The mCRC treatment did not differ according to prima-
ry tumor location. During this study, the use of anti-EG-
FR or anti-VEGF agents was limited due to the cover-
age of national insurance reimbursement. The majority 
of the patients were treated with sequential oxalipla-
tin-based or irinotecan-based combination chemother-
apy, or an alternative sequence. The median number of 
chemotherapy regimens that were used was 2 (range, 1 to 
7). One thousand and three patients (90.0%) patients re-
ceived first-line chemotherapy, and 728 patients (65.2%) 
received second-line chemotherapy. The median num-
ber of cycles of chemotherapy for first- and second-line 
chemotherapy was 8 (range, 1 to 54) and 5 (range, 1 to 32), 
respectively (Table 3). Third-line chemotherapy was ad-
ministered to 429 patients (38.5%). Single-agent capecit-
abine was used in the majority (30.3%) of these patients. 
In this study, 14.4%, 8.6%, 8.9%, 10.1%, and 13.2% of pa-
tients who received first-, second-, third-, fourth-, and 
fifth-line chemotherapy, respectively, were involved in 
a clinical trial.
Signs or symptoms of an intestinal obstruction were 
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observed in 643 patients (57.7%) (Table 1). Palliative or 
curative surgery, stenting, a combination of palliative or 
curative surgery and stenting, or an alternative method 
(e.g., conservative therapy, radiation therapy, chemo-
therapy, or concurrent chemoradiotherapy) was used to 
treat the intestinal obstruction in 352 (31.6%), 176 (15.8%), 
43 (3.9%), and 72 patients (6.4%), respectively.
Table 1. Baseline characteristics of patients with metastatic colorectal cancer
Characteristic
Primary tumor location
p value
All (n = 1,115) Right colon (n = 244) Left colon (n = 483) Rectum (n = 388)
Age, yr 62 (31–94) 66 (31–94) 62 (31–88) 60 (32–87)
Sex
 Male 685 (61.4) 130 (53.3) 289 (59.8) 266 (68.6)
 Female 430 (38.6) 114 (46.7) 194 (40.2) 122 (31.4) < 0.001a
Symptoms
Abdominal pain 462 (41.4) 154 (63.1) 210 (43.5) 98 (25.3) < 0.001a
Bleeding 316 (28.3) 22 (9.0) 118 (24.4) 176 (55.7) < 0.001a
Constipation 223 (20.0) 27 (11.1) 107 (22.2) 89 (22.9) < 0.001a
Weight loss 142 (12.7) 39 (16.0) 52 (10.8) 51 (13.1) 0.131
Bowel habit change 116 (10.4) 14 (5.7) 46 (9.5) 56 (14.4) 0.002a
Otherb 169 (15.2) 38 (15.6) 73 (15.1) 58 (14.9) 0.977
Asymptomatic 95 (8.5) 21 (8.6) 40 (8.3) 34 (8.8) 0.800
ECOG PS
0 157 (14.1) 41 (16.8) 70 (14.5) 46 (11.9)
1 430 (38.6) 91 (37.3) 163 (33.7) 176 (45.4)
2 57 (5.1) 16 (6.6) 28 (5.8) 13 (3.8)
≥ 3 18 (1.6) 3 (1.2) 12 (2.5) 3 (0.8)
NA 453 (40.6) 93 (38.1) 210 (43.5) 150 (38.7) 0.023a
Histological subtype
ADC 1,089 (97.7) 230 (94.3) 478 (99.0) 381 (98.2)
MAC 18 (1.6) 10 (4.1) 3 (0.6) 5 (1.3)
SRCC 8 (0.7) 4 (1.6) 2 (0.4) 2 (0.5) 0.011a
Histology
Well differentiated 212 (19.0) 37 (15.2) 95 (19.7) 80 (20.6)
Moderately differentiated 693 (62.2) 144 (59.0) 311 (64.4) 238 (34.3)
Poorly differentiated 126 (11.3) 36 (14.8) 46 (9.5) 44 (11.3)
Unknown 61 (5.5) 15 (6.1) 26 (5.4) 20 (5.2)
NA 23 (2.0) 12 (4.9) 5 (1.0) 6 (1.5) 0.010a
Metastatic sites
1 586 (52.6) 130 (53.3) 244 (50.5) 212 (54.6)
2 354 (31.7) 72 (29.5) 157 (32.5) 125 (32.2)
≥ 3 175 (15.7) 42 (17.2) 82 (17.0) 51 (13.1) 0.448
Values are presented as median (range) or number (%).
ECOG, Eastern Cooperative Oncology Group; PS, performance status; NA, not available; ADC, adenocarcinoma; MAC, muci-
nous adenocarcinoma; SRCC, signet-ring cell carcinoma. 
ap < 0.05.
bAnal pain, low stool caliber, abdominal mass.
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Oncological outcomes according to primary tumor 
location and chemotherapy with molecularly target-
ed agents
The median OS of all mCRC patients was 17.8 months 
(95% CI, 16.7 to 18.9), although differences were observed 
according to primary tumor location (Table 4). The me-
dian OS of patients with tumors originating in the right 
colon was significantly shorter than that of patients 
whose tumors had originated in the left colon or rectum 
(13.7 months [95% CI, 12.0 to 15.5] vs. 18.0 months [95% 
CI, 16.3 to 19.7] or 19.9 months [95% CI, 18.5 to 21.3], re-
spectively; p = 0.003) (Fig. 1).
Chemotherapy with molecularly targeted agents 
The majority of patients were treated with several che-
motherapy regimens. Compared to patients who were 
not administered chemotherapy (i.e., receiving best sup-
portive care only), a survival benefit was observed in the 
chemotherapy group, with a median OS of 19.2 (95% CI, 
18.1 to 20.3) months compared to 3.2 (95% CI, 1.5 to 4.9) 
months for the best supportive care group (Table 4). De-
spite anti-EGFR and anti-VEGF agents being restricted 
by the coverage of national insurance reimbursement, 
the use of anti-EGFR and anti-VEGF agents was asso-
ciated with a prolonged survival. The median OS of 
patients who had received combination chemotherapy 
with anti-EGFR or anti-VEGF agents was significantly 
longer than that of patients who had received combina-
tion chemotherapy alone (22.0 months [95% CI, 19.5 to 
24.5] vs. 18.5 months [95% CI, 17.2 to 19.7], respectively; p < 
0.05). This was particularly the case for patients with pri-
mary tumors originating from the left colon or rectum 
(Fig. 2). For patients treated with first-line chemothera-
py, the median PFS was comparable to the median OS 
(7.0 months [95% CI, 6.5 to 7.5] vs. 8.9 months [95% CI, 8.1 
to 9.8] for the chemotherapy alone and chemotherapy 
with molecularly targeted agent groups, respectively; p 
= 0.002). The effect of chemotherapy with molecularly 
targeted agents was more pronounced in left colon and 
Table 2. Metastatic patterns according to the primary tumor location
Metastatic site
Primary tumor location
p value
All (n = 1,115) Right colon (n = 244) Left colon (n = 483) Rectum (n = 388)
Liver 836 (75.0) 170 (69.7) 385 (79.7) 281 (72.4) 0.005a
Extra-regional lymph node 347 (31.1) 78 (32.0) 145 (30.0) 124 (32.0) 0.786
Lung 333 (29.9) 55 (22.5) 144 (29.8) 134 (34.5) 0.006a
Peritoneum 180 (16.1) 70 (28.7) 79 (16.4) 31 (8.0) < 0.001a
Bone 77 (6.9) 11 (4.5) 34 (7.0) 32 (8.2) 0.194
Ovary 30 (2.7) 7 (2.9) 19 (3.9) 4 (1.0) 0.031a
Brain 9 (0.8) 1 (0.4) 4 (0.8) 4 (1.0) 0.695
Values are presented as number (%).
ap < 0.05.
Table 3. Characteristics of the first- and second- line che-
motherapy regimen 
Characteristic
Chemotherapy regimen
First-line 
(n = 1,003)
Second-line 
(n = 728)
No. of cycles 8 (1–54) 5 (1–32)
≤ 12 866 (86.3) 668 (91.8)
> 12 137 (13.7) 60 (8.2)
Chemotherapy regimen
Oxaliplatin-based regimena 550 (54.8) 141 (19.4)
Irinotecan-based regimenb 126 (12.5) 365 (50.1)
Anti-EGFR agentsc 41 (4.1) 30 (4.1)
Anti-VEGF agentsd 138 (13.7) 61 (8.4)
Capecitabine 57 (5.7) 48 (6.6)
Other 93 (9.2) 83 (11.4)
Values are presented as median (range) or number (%).
EGFR, epidermal growth factor receptor; VEGF, vascular 
endothelial growth factor.
a5-Fluorouracil/leucovorin/oxaliplatin or capecitabine/oxali-
platin.
b5-Fluorouracil/leucovorin/irinotecan or capecitabine/irino-
tecan.
cCetuximab or panitumumab.
dBevacizumab.
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Table 4. OS and PFS according to primary tumor location and treatment regimen
Characteristic
Primary tumor location
p valueAll 
(n = 1,115)
Right colon 
(n = 244)
Left colon 
(n = 483)
Rectum 
(n = 388)
OS, mon 17.8 (16.7–18.9) 13.7 (12.0–15.5) 18.0 (16.3–19.7) 19.9 (18.5–21.3) 0.003a
Treatment regimenb 19.2 (18.1–20.3) 16.2 (14.0–18.3) 19.4 (17.9–21.0) 20.8 (19.5–22.1) 0.086
Chemotherapy with targeted agentsc 22.0 (19.5–24.5) 17.2 (12.4–22.0) 25.3 (20.9–29.7) 22.0 (17.2–26.8) 0.018a
Chemotherapy without targeted agents 18.5 (17.2–19.7) 15.6 (13.1–18.1) 17.9 (15.8–20.0) 20.1 (18.8–21.4) 0.166
Best supportive care 3.2 (1.5–4.9) 2.5 (0.4–4.6) 5.4 (2.2–8.6) 2.8 (0.0–6.5) 0.122
PFS, mon
First-line chemotherapy 7.6 (7.1–8.0) 7.4 (6.6–8.2) 7.8 (7.2–8.3) 7.5 (6.8–8.2) 0.265
Chemotherapy with targeted agentsc 8.9 (8.1–9.8) 7.5 (5.7–9.3) 9.5 (8.4–10.7) 8.7 (6.8–10.5) 0.023a
Chemotherapy without targeted agents 7.0 (6.5–7.5) 7.1 (6.2–8.1) 6.6 (5.9–7.3) 7.0 (6.5–7.5) 0.809
Second-line chemotherapy 3.7 (3.3–4.0) 3.5 (2.7–4.2) 3.6 (3.0–4.2) 3.9 (3.3–4.0) 0.225
Chemotherapy with targeted agentsc 4.4 (3.8–5.0) 3.9 (2.3–5.4) 4.8 (3.9–5.7) 4.1 (3.0–5.2) 0.092
Chemotherapy without targeted agents 3.7 (3.3–5.0) 3.9 (2.3–5.4) 4.8 (3.9–5.7) 4.1 (3.0–5.2) 0.712
Values are presented as median (range).
OS, overall survival; PFS, progression-free survival.
ap < 0.05.
bPatients were treated by surgical resection with or without chemotherapy or chemotherapy alone.
cPatients were treated by chemotherapy with anti-epidermal growth factor receptor and/or anti-vascular endothelial growth 
factor agents.
Figure 1. Kaplan-Meier curves of overall survival (OS) of pa-
tients with metastatic colorectal cancer according to prima-
ry tumor location. CI, confidence interval. ap < 0.05. 
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Figure 2. Kaplan-Meier curves of overall survival (OS) based 
on chemotherapy with molecularly targeted agents according 
to primary tumor location. CI, confidence interval. ap < 0.05.
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rectal cancer patients than right colon cancer patients (p 
< 0.05). However, for patients treated with second-line 
chemotherapy, the effect of molecularly targeted agents 
was reduced and no significant differences were ob-
served with respect to primary tumor location.
KRAS mutation status and primary tumor location
The KRAS genetic testing was performed in 516 of the 
1,115 patients (46.3%) included in this study. At the time, 
only exon 2 was screened due to the definition of a wild-
type KRAS gene. KRAS genetic testing was performed 
by peptide nucleic acid-mediated real-time polymerase 
chain reaction clamping, direct sequencing, or pyrose-
quencing. The mutant KRAS gene was detected in 179 
patients (34.7%) and was more frequently observed in 
patients with primary right colon cancer (p = 0.004) (Ta-
ble 5). Codon 12 mutations were detected in 132 patients 
(73.7%) and codon 13 mutations were detected in 42 pa-
tients (23.5%). The KRAS mutation status was unknown 
for the remaining five patients (2.8%). In this study, the 
KRAS mutation status itself did not influence the me-
dian OS. However, in patients with the wild-type KRAS 
gene, chemotherapy with molecularly targeted agents 
and the primary tumor location correlated with OS (Ta-
Table 5. KRAS mutation status according to primary tumor location
Primary tumor location
p value
All Right colon Left colon Rectum
KRAS mutation status 516 100 246 170
Wild-type 337 (65.3) 51 (51.0) 170 (69.1) 116 (68.2)
Mutant 179 (34.7) 49 (49.0) 76 (30.9) 54 (31.8) 0.004a
KRAS mutation site 179 49 76 54
Codon 12 132 (73.7) 34 (69.4) 58 (73.6) 40 (74.1)
Codon 13 42 (23.5) 14 (28.6) 16 (21.1) 12 (22.2)
Unknown 5 (2.8) 1 (2.0) 2 (2.6) 2 (3.7) 0.873
Values are presented as number (%). 
ap < 0.05.
Table 6. OS and PFS according to primary tumor location and KRAS mutation status 
Characteristic
Primary tumor location
p valueAll
(n = 516)
p value
Right colon
(n = 100)
Left colon 
(n = 246)
Rectum 
(n = 170)
OS, mon
Wild-type KRAS 20.6 (18.5–22.7) 0.310 15.6 (12.6–18.5) 21.7 (17.6–25.8) 21.6 (18.6–22.7) 0.008a
Mutant KRAS 20.7 (18.7–22.8) 17.5 (13.2–21.8) 20.8 (18.0–23.6) 21.0 (15.6–26.4) 0.689
First-line chemotherapy
Overall PFS, mon 7.6 (7.2–8.0) 7.4 (6.6–8.2) 7.8 (7.2–8.3) 7.5 (6.8–8.0) 0.265
Wild-type KRAS 8.2 (7.5–8.9) 7.4 (5.0–9.7) 8.6 (7.9–9.3) 8.5 (7.3–9.7) 0.077
Mutant KRAS 8.3 (7.5–9.2) 0.692 8.3 (6.4–10.3) 7.8 (6.1–9.5) 8.0 (6.4–9.6) 0.892
Second-line chemotherapy
PFS, mon 3.7 (3.3–4.0) 3.5 (2.7–4.2) 3.6 (3.0–4.2) 3.9 (3.3–4.5) 0.225
Wild-type KRAS 4.1 (3.5–4.7) 3.1 (2.0–4.2) 3.8 (2.7–4.9) 4.8 (3.5–4.7) 0.044a
Mutant KRAS 3.5 (2.8–4.2) 0.259 3.7 (2.4–5.0) 2.6 (1.4–3.7) 3.7 (2.7–4.7) 0.223
Values are presented as median (range).
OS, overall survival; PFS, progression-free survival.
ap < 0.05.
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bles 6 and 7). Patients with primary left colon or rectal 
tumors that expressed the wild-type KRAS gene had a 
significant longer median OS than patients with prima-
ry right colon tumors (21.7 months [95% CI, 17.6 to 25.8] 
or 21.6 months [95% CI, 18.6 to 22.7] vs. 15.6 months [95% 
CI, 12.6 to 18.5], respectively; p = 0.008).
Surgical resection and primary tumor location
Surgical resection of the primary and metastatic tu-
mors was associated with a prolonged survival. Cura-
tive resections were performed in 218 patients (19.6%). 
One hundred and thirty-eight patients (12.4%) under-
went surgical resection as the initial treatment and 80 
patients (7.2%) underwent surgical resection during 
first- or second-line chemotherapy. Curative resections 
were usually performed by resecting the primary tumor 
and metastatic tumors with or without radiofrequency 
ablation. Palliative resections were performed in 330 
patients (29.6%). The majority of palliative resections 
were primary tumor resections (Table 8). Irrespective of 
whether the surgical resections were curative, tumor re-
section was associated with a more favorable prognosis. 
The median OS was 38.9 months (95% CI, 34.0 to 43.8) 
for patients who had undergone curative resection, 19.7 
months (95% CI, 18.0 to 21.4) for patients who had un-
dergone palliative resection, and 12.1 months (95% CI, 
11.2 to 13.1) for patients who did not undergo surgical re-
section (p = 0.007). However, in patients who underwent 
Table 7. OS and PFS according to chemotherapy regimen and KRAS mutation status 
Characteristic
Chemotherapy 
p value
With targeted agentsa Without targeted agents
OS, mon
Wild-type KRAS 24.0 (20.6–26.7) 18.9 (17.2–20.7) 0.015b
Mutant KRAS 21.8 (16.8–26.7) 20.1 (18.1–22.1) 0.670
PFS, mon
First-line chemotherapy
Wild-type KRAS 9.0 (7.9–10.1) 7.6 (6.4–8.7) 0.063
Mutant KRAS 9.1 (7.6–10.7) 7.8 (6.3–9.2) 0.093
Second-line chemotherapy
Wild-type KRAS 4.6 (3.7–5.5) 3.5 (2.6–4.6) 0.128
Mutant KRAS 4.4 (2.7–4.2) 3.1 (2.3–4.0) 0.006b
Values are presented as median (range).
OS, overall survival; PFS, progression-free survival.
aAnti-epidermal growth factor receptor and anti-vascular endothelial growth factor agents.
bp < 0.05.
Table 8. Surgical outcome according to the primary tumor location
Characteristic
Primary tumor location
p value
All (n = 548) Right colon (n = 123) Left colon (n = 235) Rectum (n = 190)
Curative surgery 218 (19.6) 36 (16.5) 93 (42.7) 89 (40.8)
Palliative surgery 330 (29.6) 87 (26.4) 142 (43.0) 101 (30.6)
OS, mon
Curative surgery 38.9 (34.0–43.8) 38.9 (25.0–52.8) 41.8 (34.2–49.3) 35.0 (27.8–42.2) 0.224
Palliative surgery 19.7 (18.0–21.4) 16.6 (14.5–18.6) 19.7 (17.1–22.3) 21.2 (18.1–21.4) 0.078
None 12.1 (11.2–13.1) 9.9 (6.3–13.5) 11.5 (9.6–13.5) 13.2 (10.9–15.6) 0.019a
Values are presented as number (%) or median (range).
OS, overall survival.
ap < 0.05.
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curative or palliative resection, no significant differenc-
es in OS were observed with respect to primary tumor 
location (p = 0.224 and p = 0.078, respectively).
Difference in the numbers and pattern of metastatic 
sites
The number and pattern of metastatic sites were asso-
ciated with survival. In patients with a single metastatic 
site, the median OS differed according to the metastatic 
site. The median OS was 19.8 (95% CI, 17.5 to 22.1), 27.8 
(95% CI, 23.2 to 32.4), 18.0 (95% CI, 11.0 to 25.0), 24.9 (95% 
CI, 21.5 to 28.3), 4.1 (95% CI, 2.5 to 5.7), and 28.4 months 
(95% CI, 26.5 to 30.3) months for patients with liver, lung, 
peritoneal, extra-regional lymph node, bone and ovari-
an metastases alone, respectively (p = 0.031). The OS of 
a patient with brain metastasis alone was 15.7 months. 
A comparison of the different metastatic sites revealed 
that the survival of patients with peritoneal metastasis 
was significantly poorer than the survival of patients 
with liver (p < 0.05), lung (p = 0.002), or extra-regional 
lymph node (p = 0.001) metastases. In contrast, no signif-
icant differences were observed for patients with bone or 
ovarian metastases (p = 0.481 and p = 0.124, respectively). 
The number of metastatic sites exhibited a statistically 
significant effect on survival. The median OS of patients 
with a single metastatic site, including those with a soli-
tary metastasis, was significantly longer than that of pa-
tients with multiple metastatic sites (21.2 months [95% 
CI, 19.2 to 23.2] vs. 16.7 months [95% CI, 15.0 to 18.4] or 
13.1 months [95% CI, 10.8 to 15.4] for 2 and ≥ 3 metastatic 
sites, respectively; p < 0.001) (Fig. 3).
Prognostic factors
In the univariate analysis, age, the presence of an un-
derlying disease, Eastern Cooperative Oncology Group 
(ECOG) performance status (PS), the number of meta-
static sites, the use of molecularly targeted agents, sur-
gical resection, and primary tumor location correlated 
with OS. Due to the extent of missing data for the ECOG 
PS, the use of molecularly targeted agents, and KRAS 
mutation status, these factors were excluded from the 
multivariate analysis. In the multivariate analysis, the 
number of metastatic sites, surgical resection (curative 
and palliative), and primary tumor location were associ-
ated with OS (Table 9).
DISCUSSION
In this study, we demonstrate that the primary tumor 
location influences the metastatic sites and prognosis 
of patients with mCRC. The pattern of metastasis dif-
fered according to primary tumor location. Right colon 
cancer metastasized more frequently to the peritoneum 
and ovaries and left colon and rectal cancer metastasized 
more frequently to the lungs. This difference was also re-
ported in recurrence patterns after curative resection or 
the initial presentation of metastatic disease. Colon can-
cer patients presented more frequently with intra-ab-
dominal metastases, including peritoneal, omental, and 
ovarian metastases. Left colon cancer patients were as-
sociated with an increased risk of metastatic spread to 
the liver, whereas rectal cancer patients were associated 
with an increased risk of local recurrence and metastatic 
spread to the extra-abdominal sites, including the lungs 
and brain [13-16]. These differences affected the initial 
evaluation of CRC and clinical practice. Although lim-
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Figure 3. Kaplan-Meier curves of overall survival (OS) ac-
cording to the number of metastatic sites. CI, confidence 
interval. ap < 0.05. 
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ited evidence exists regarding the pattern of spread of 
CRCs, there are several potential explanations for the 
differences in metastatic patterns, including differences 
in tumor genetics, biology, and histology [16,17], as well 
as, anatomically distinct and discrete lymphatic and vas-
cular drainage regions [18].
We have previously established that chemotherapy 
with or without molecularly targeted agents is associ-
ated with prolonged survival in patients with mCRC [8-
12]. In this study, we also demonstrate that the survival 
of patients with mCRC differs according to the primary 
tumor location, with a median OS of 13.7, 18.0, and 19.9 
months for the right colon, the left colon, and the rec-
tum, respectively. Moreover, in patients who received 
chemotherapy with molecularly targeted agents the sur-
vival benefits were more pronounced for those with tu-
mors originating in the left colon and rectum compared 
to those with tumors originating in the right colon 
(Table 7). Although controversial, several studies [19-21] 
have shown that there may be a survival difference be-
tween patients with left and right colon cancer. Meguid 
et al. [19]. and Benedix et al. [20] reported that patients 
with right colon cancer had a poorer prognosis than pa-
tients with left colon cancer. However, Weiss et al. [21] 
reported no significant differences in survival between 
patients with right and left colon cancer. Because these 
studies focused mainly on early-stage colon cancer, rec-
tal cancer was excluded, due to the different treatments 
for localized disease. Patients with mCRC were relatively 
few in number and the pathological information on the 
tumors was limited. Thus, the influences of the primary 
tumor location on the clinical outcomes of patients with 
mCRC remains controversial. 
More recently, responses to chemotherapy with mo-
lecularly targeted agents have been shown to differ 
according to primary tumor location. The addition of 
bevacizumab to combination chemotherapy for mCRC 
could benefit patients with primary left colon tumors 
[22,23]. In addition, the anti-EGFR agent, cetuximab, 
could be beneficial in the treatment of patients with pri-
mary left colon tumors [24,25]. In this study, KRAS ge-
netic testing was performed in selected mCRC patients, 
due to the limited coverage of national insurance reim-
bursement. KRAS mutation status differed according to 
Table 9. Univariate and multivariate analyses of overall survival in metastatic colorectal cancer 
Characteristic
Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
Age, yr
≤ 65 1 1
> 65 1.39 (1.23–1.58) < 0.001a 1.06 (0.93–1.20) 0.394
Underlying disease
Absent 1 -
Present 1.03 (0.91–1.17) 0.646 - -
Primary tumor location
Right colon 1 1
Left colon 0.80 (0.68–0.94) 0.007a 0.81 (0.68–0.95) 0.010a
Rectum 0.76 (0.64–0.90) 0.001a 0.78 (0.64–0.90) 0.001a
Metastases
Single 1 1
Multiple 1.52 (1.34–1.73) < 0.001a 1.52 (1.33–1.72) < 0.001a
Surgery
None 1 1
Curative surgery 0.22 (0.18–0.27) < 0.001a 0.24 (0.20–0.29) < 0.001a
Palliative surgery 0.58 (0.50–0.67) < 0.001a 0.58 (0.50–0.67) < 0.001a
HR, hazard ratio; CI, confidence interval.
ap < 0.05.
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the primary tumor location. KRAS gene mutations oc-
curred more frequently in patients with right colon can-
cer. In patients, whose tumors expressed the wild-type 
KRAS gene, the prognosis was significantly better for left 
colon and rectal cancer patients than right colon can-
cer patients. These findings were consistent with those 
of recently published studies. In the NCIC-CTC-CO.17 
trial [26], the efficacy of cetuximab in chemorefractory 
mCRC patients was significantly higher for those with 
tumors originating in the left colon. The median PFS 
for cetuximab-treated patients with primary tumors 
originating in the left and right colon was 5.4 and 1.9 
months, respectively (p = 0.002). An analysis of the AIO 
KRK-0104 trial comparing first-line therapies using 
cetuximab, capecitabine, and irinotecan with cetuximab, 
capecitabine, and oxaliplatin [24] reported that patients 
with primary tumors originating in the left colon had a 
longer OS and PFS compared to patients whose primary 
tumors had originated in the right colon. 
CRC is a heterogeneous disease with respect to molec-
ular carcinogenesis and morphological multistep path-
ways. Molecular alterations in CRC may exert their ef-
fects through three major pathways: MSI, chromosomal 
instability (CIN), and CpG island methylator phenotype 
(CIMP). These pathways illustrate alterations of genes 
and critical pathways, including defects of DNA mis-
match repair genes, APC gene with Wnt signaling acti-
vation, TP53 gene with inactivation of p53 pathway, RAS 
and BRAF gene with mitogen-activated protein kinase 
signaling pathway, PI3KCA gene with PIK3 signaling, 
inactivation of transforming growth factor β pathway, 
epithelial-to-mesnechymal transition genes and MYC 
gene amplification, and among others [27,28]. Moreover, 
these genetic alterations affect morphological multistep 
pathways, such as the classic adenoma-carcinoma and 
serrated neoplasia pathways. These alterations can occur 
individually or in combination, resulting in the growth 
of tumors with different clinical and morphological 
characteristics [6,29-31]. Although CIN predominantly 
occurs in sporadic tumors, irrespective of their anatom-
ical site, sporadic tumors harboring MSIs are localized, 
especially in the proximal colon [6,32,33]. The major-
ity of CIMP-high tumors are associated with MSI, the 
proximal colon, and KRAS and BRAF mutation [34]. The 
clinical characteristics of CIMP CRC patients have been 
compared to those of CRC patients with MSI. The prog-
nosis of CRC patients with MSI-high tumors is more fa-
vorable compared to the prognosis of CRC patients with 
CIN [35]. However, the CIMP-high tumors are associated 
with reduced colon cancer mortality rates. Additionally, 
BRAF mutation status is frequently identified in tumors 
with the CIMP-high tumors as being associated with a 
high colon cancer specific mortality [36,37]. In the pres-
ent study, although the molecular characteristics of CRC 
(e.g., BRAF mutation, CIMP, and MSI status) could not 
be evaluated, the prognosis of patients with right colon 
cancer was poorer compared to that of patients with left 
colon or rectal cancer. It may be related to these mo-
lecular alterations and clinical characteristics that, at the 
time of initial diagnosis, metastatic right colon cancer is 
associated with a greater tumor burden than left colon 
or rectal cancer. 
Surgical resection is the treatment of choice for pa-
tients with resectable mCRC [38]. However, palliative re-
section of the primary tumor in mCRC is controversial. 
Although selection bias was present, several retrospec-
tive analyses [39,40] have demonstrated that palliative 
resection of the primary tumor is associated with im-
proved survival, especially in relatively young patients 
with a good PS and tumors that were not poorly differ-
entiated. Our study also revealed that tumor resection, 
whether curative or palliative, improved the survival of 
patients with primary tumors at any location. Clinical 
trials are needed to validate these finding.
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KEY MESSAGE 
1. Primary tumor location inf luences the meta-
static sites and prognosis of patients with meta-
static colorectal cancer.
2. The effect of chemotherapy with molecularly 
targeted agents is more pronounced in primary 
left side tumor location. 
3. Surgical resection of the tumor (curative or pal-
liative) may be influenced the survival.
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